Virology News and Research

Latest Virology News and Research

J&JPRD submits New Drug Application to FDA for rivaroxaban

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a New Drug Application to the U.S. Food and Drug Administration for rivaroxaban, an investigational, oral, once-daily anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

6 Jan 2011

Scientists identify prognostic biomarker to treat patients with HCV

Scientists at Inserm and Institut Pasteur have performed biomarker discovery on patients being treated for chronic hepatitis C infection. Their work, published in The Journal of Clinical Investigation, demonstrates that the plasma levels of the protein IP-10 predict, prior to treatment initiation, the efficacy of treatment with pegylated-interferon and ribavirin.

6 Jan 2011

Study provides new insights into how viruses establish chronic infections

Walter and Eliza Hall Institute researchers in Melbourne, Australia, have discovered how a key viral gene helps viruses evade early detection by the immune system. Their finding is providing new insights into how viruses are able to establish chronic infections, leading scientists to reevaluate their approaches to viral vaccine development.

6 Jan 2011

Unique vaccine produces long-lasting anti-cocaine immunity in mice

Researchers from The Scripps Research Institute, Weill Cornell Medical College, and Cornell University have produced a long-lasting anti-cocaine immunity in mice by giving them a unique vaccine that combines bits of the common cold virus with a particle that mimics cocaine.

5 Jan 2011

Men are more willing to receive HPV vaccine, trend may help reduce cancer deaths

Men are more willing to receive human papillomavirus vaccine when they learn the vaccine can prevent cancer, according to a recent University of North Carolina at Chapel Hill study.

5 Jan 2011

Safe vaccine protects mice against effects of cocaine

Researchers have produced a lasting anti-cocaine immunity in mice by giving them a safe vaccine that combines bits of the common cold virus with a particle that mimics cocaine.

5 Jan 2011

Researchers develop unique vaccine that produces long-lasting anti-cocaine immunity in mice

5 Jan 2011

Anadys begins ANA598 Phase IIb study for hepatitis C

Anadys Pharmaceuticals, Inc. announced today that it has initiated the planned Phase IIb study of ANA598 in combination with pegylated interferon and ribavirin. The protocol for the study has been cleared by the United States Food and Drug Administration and Health Canada.

4 Jan 2011

Vaccine blocks cocaine high in mice - human trials likely

Researchers have produced a lasting anti-cocaine immunity in mice by giving them a safe vaccine that combines bits of the common cold virus with a particle that mimics cocaine.

4 Jan 2011

Flu outbreak peak yet to come: Experts

Parents of kids returning to school in the UK after Christmas holidays have been warned of a surge in flu cases. Professor John Oxford, a leading virologist at St Bartholomew’s and the Royal London Hospital explained that children returning to school in the past prompted a rise in the number of flu cases. “You tend to get a surge,” the professor said. “I would anticipate a surge, but how long that will last is difficult to say.” He added, “This virus is not going to go away next week. Even if it’s already peaked, it’s still going to be around for the next couple of weeks and it’s still worthwhile being vaccinated at this stage.”

4 Jan 2011

Hepatitis A scare at Long Island church

Health officials have warned that parishioners who received Holy Communion during Christmas Mass at a church on Long Island may have been exposed to hepatitis A and may need vaccinated as soon as possible. Particularly those who received Communion at the 10.30am and 12pm (local time) masses on December 25, 2010, at Our Lady of Lourdes Church in Massapequa Park should get the shots.

4 Jan 2011

Trial to eliminate deadly Dengue begins

The 12 week programme costing $18 million named ‘Eliminate Dengue’ has commenced. Mosquitoes bearing a special bacteria would be released into the wild around Cairns as part of a trial to rid the area of the insects that carry Dengue fever.

4 Jan 2011

AHF to supply $1 million in free AIDS drugs to Florida's disenrolled and wait listed HIV/AIDS patients

As the State of Florida grapples with a budget shortfall that has crippled its AIDS Drug Assistance Program (ADAP) and forced the state to potentially disenroll 350 Florida patients already on ADAP as well as place nearly 2,400 low-income Floridians on waiting lists to access lifesaving medications, AIDS Healthcare Foundation (AHF) has proposed an innovative plan to help state health officials and displaced HIV/AIDS patients bridge the transition to private patient assistance programs run by the major pharmaceutical companies.

4 Jan 2011

Mothers can play a key role in convincing college-aged women to receive HPV vaccine

Even after young women reach adulthood, their mothers can play a key role in convincing them to receive the human papillomavirus vaccine, new research suggests.

3 Jan 2011

Flu worries continue

The flu season continues to affect more people. Experts have warned the Britons are still at risk as the surge in flu cases has still not yet peaked. The cases would increase they warn, over the next two to four weeks. World Health Organization released figures that show the rate of influenza-like illnesses is still low across continental Europe but has risen dramatically in Britain since the flu season began in October.

3 Jan 2011

FDA approves 200 mg formulation of INTELENCE for HIV-1

The U.S. Food and Drug Administration (FDA) approved a label update to include a 200 mg formulation of INTELENCE® (etravirine), a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for the treatment of human immunodeficiency virus (HIV-1) in treatment-experienced adults with resistance to an NNRTI and other antiretroviral (ARV) agents.

3 Jan 2011

Genocea announces close of $35 million Series B venture financing round

Genocea Biosciences Inc., a vaccine discovery and development company pioneering a new class of T cell-based vaccines, today announced that it has closed a $35 million Series B round of venture financing, with new investors Johnson & Johnson Development Corporation (JJDC), Skyline Ventures and MP Healthcare Venture Management, Inc. (MPH) joining existing investors Polaris Venture Partners, Lux Capital Management, SR One, Cycad Group, Auriga Partners and Morningside Ventures.

3 Jan 2011

Researchers study molecular mechanisms in early stages of IPN virus infection

Infectious pancreatic necrosis is a serious disease that leads to enormous losses in the salmon industry each year. The virus that causes the disease, IPN, is very prevalent in farmed salmon and trout in Norway. The virus attacks a wide diversity of hosts and has been found to occur in many different fish species, in addition to shellfish and molluscs.

30 Dec 2010

New study confirms pancreas disease infects horizontally from population to population in seawater phase

Researchers and the salmon industry have been debating whether fingerling from freshwater farms can be a source of the virus that causes pancreas disease: salmonid alfavirus. The results of a new doctoral study show that this is not the case: pancreas disease transmits horizontally in the seawater phase and infection in fresh water has little bearing on how the disease spreads.

29 Dec 2010

Molecular interaction between structural HCV protein and protein critical to viral replication identified

Scientists from the Florida campus of The Scripps Research Institute have identified a molecular interaction between a structural hepatitis C virus protein (HCV) and a protein critical to viral replication. This new finding strongly suggests a novel method of inhibiting the production of the virus and a potential new therapeutic target for hepatitis C drug development.

29 Dec 2010

Virology News and Research

Latest Virology News and Research

J&JPRD submits New Drug Application to FDA for rivaroxaban

Scientists identify prognostic biomarker to treat patients with HCV

Study provides new insights into how viruses establish chronic infections

Unique vaccine produces long-lasting anti-cocaine immunity in mice

Men are more willing to receive HPV vaccine, trend may help reduce cancer deaths

Safe vaccine protects mice against effects of cocaine

Researchers develop unique vaccine that produces long-lasting anti-cocaine immunity in mice

Anadys begins ANA598 Phase IIb study for hepatitis C

Vaccine blocks cocaine high in mice - human trials likely

Flu outbreak peak yet to come: Experts

Hepatitis A scare at Long Island church

Trial to eliminate deadly Dengue begins

AHF to supply $1 million in free AIDS drugs to Florida's disenrolled and wait listed HIV/AIDS patients

Mothers can play a key role in convincing college-aged women to receive HPV vaccine

Flu worries continue

FDA approves 200 mg formulation of INTELENCE for HIV-1

Genocea announces close of $35 million Series B venture financing round

Researchers study molecular mechanisms in early stages of IPN virus infection

New study confirms pancreas disease infects horizontally from population to population in seawater phase

Molecular interaction between structural HCV protein and protein critical to viral replication identified

Microplate-based assays in virology research eBook eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting